Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis by Manfredonia, Francesco et al.
© 2008 Dove Medical Press Limited.   All rights reserved
Neuropsychiatric Disease and Treatment 2008:4(2) 321–336 321
EXPERT OPINION
Review of the clinical evidence for interferon β
1a (Rebif  ®) in the treatment of multiple sclerosis
Francesco Manfredonia1
Livia Pasquali1
Angela Dardano2
Alfonso Iudice1
Luigi Murri1
Fabio Monzani2
1Department of Neuroscience and 
2Department of Internal Medicine, 
University of Pisa, Pisa, Italy
Correspondence: Fabio Monzani
Department of Internal Medicine, 
University of Pisa, Via Roma 67, 56126 
Pisa, Italy
Tel +39 050 993 490
Fax +39 050 553 235
Email fmonzani@med.unipi.it
Abstract: Interferon (INF) β 1a 22 or 44 µg (Rebif ®) administered s.c. 3 times a week (t.i.w) is a 
well established immunomodulating treatment for relapsing remitting multiple sclerosis (RRMS). 
This review focuses on its mechanisms of action, evidence of efﬁ  cacy, safety, and tolerability. 
Several pharmacodynamic properties explain the immunomodulatory actions of INF β 1a 22 
or 44 µg s.c. t.i.w. Pivotal trials and post-marketing studies proved that the drug is effective in 
reducing disease activity and likely in slowing disease progression. Head-to-head comparative 
studies with other marketed INFs β in RRMS suggested a better therapeutic response associated 
with higher doses and frequency of administration of Rebif ®. Additional evidence indicated a 
beneﬁ  cial effect of INF β 1a in patients with clinically isolated syndromes (CIS) suggestive of 
MS, as treatment reduced time to conversion to clinically deﬁ  nite (CD) disease. Further, although 
the drug did not prove to slow time to progression there were beneﬁ  ts on relapse- and MRI-related 
secondary outcome measures in secondary progressive (SP) MS. Pivotal trials, their cross-over 
extensions, and post-marketing studies consistently showed that INF β 1a 22 or 44 µg s.c. t.i.w. 
is safe and well tolerated, as adverse drug reactions are usually mild and manageable.
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Introduction
Multiple sclerosis (MS) is an immune mediated disease characterized by a neuroin-
ﬂ  ammatory process affecting the white matter in the central nervous system (CNS). 
It results in the occurrence of recurrent acute neurological impairment which remits 
in the majority of patients with or without sequeleae (relapsing remitting [RR] MS) 
(Compston et al 2002). However, a neurodegenerative process leading to axonal loss 
and matrix destruction takes place over the course of years, and is implicated in sus-
tained, irreversible neurological disability. Neuronal loss is more prominent when the 
disease takes a progressive course after years of RR episodes (secondary progressive 
[SP] MS) (Rovaris et al 2006) or when clinical manifestations are progressive from 
onset (primary progressive [PP] MS) (Thompson et al 1997).
Over the last 15 years, pivotal randomized, multicenter, double-blind, placebo-
controlled studies have led to the market licence of interferons beta (IFNs β) for the 
treatment of RR MS (The IFNB Multiple Sclerosis Study Group 1993; Jacobs et al 
1996; PRISMS Study Group 1998) and to its worldwide use in clinical settings. Addi-
tional studies have then assessed efﬁ  cacy of IFNs β in clinically isolated syndromes 
(CIS) likely to develop MS (Jacobs et al 2000; Comi et al 2001), and in SP forms of 
the disease with superimposing relapses (European Study Group on Interferon beta-1b 
in Secondary Progressive MS 1998; Secondary Progressive Efﬁ  cacy Clinical Trial of 
Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group 2001).
In this review we focused on clinical evidence of efﬁ  cacy and safety of IFN β 1a 
22 and 44 µg s.c. administered 3 times in a week (t.i.w.), a IFN β preparation that is 
currently available for treatment of patients with RR MS.Neuropsychiatric Disease and Treatment 2008:4(2) 322
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Firstly, we examined the mechanisms of action of IFNs β 
as a class, with reference to in vivo and in vitro evidence of 
action of IFN β 1a 22 and 44 µg s.c. Secondly, we discussed 
the results of trials that led to the marketing approval of IFN 
β 1a 22 and 44 µg s.c. t.i.w. and their extensions. Thirdly, we 
focused on selected longitudinal follow-up studies looking 
at a conﬁ  rmation of pivotal trial results and trying to infer 
the long-term beneﬁ  t of IFN β 1a 22 and 44 µg s.c. t.i.w., 
by a systematic review of the literature. We then provided 
an overlook of clinical trials that showed evidence of the 
beneﬁ  t of IFN β 1a 22 and 44 µg s.c. t.i.w. beyond RRMS, 
in both SPMS and CIS. Finally, we considered the safety and 
tolerability proﬁ  le of the drug.
Subtypes of interferons
IFNs β can be distinguished into IFN β 1b and 1a on the 
basis of structural differences that conversely depend on the 
recombinant technique of production (Runkel et al 1998). 
IFN β 1b (Betaseron®, Berlex Laboratories, Montville NJ; 
Betaferon, Schering AG, Berlin, Germany) is obtained by 
cloning the molecule in bacterial cells that are unable to 
glycosylate the recombinant protein, remove the N-terminal 
methionine during translation and replace one of the three 
cysteines with serine to maintain structural stability, whereas 
IFN β 1a is instead produced in mammalian cells, and is 
identical to the natural form of human IFN β.
Among IFNs β 1a two different treatments are currently 
available, one requiring a 30 µg dose administered i.m. once 
weekly (q.w.) (Avonex®; Biogen, Cambridge, MA), and the 
other that is given s.c. t.i.w. (Rebif ®; Serono International SA, 
Geneva, Switzerland) at a dose of either 22 or 44 µg.
Because of structural differences, IFN β 1b is less active 
than IFNs β 1a (Antonetti et al 2002), and higher doses every 
other day (q.o.d.) are needed to achieve an equivalent effect. 
These factors may account for the higher degree of immu-
nogenicity and the likelihood of development of binding 
and neutralizing antibodies (NAbs) over the course of treat-
ment (Bertolotto et al 2004). 28%– 47% of patients develop 
NAbs to INF β 1b, 12%–28% to INF β 1a s.c. (Rebif ®) and 
2%– 6% to INF β 1a i.m. (Avonex®) (Bertolotto et al 2004), 
and their production has been associated with deterioration 
of therapeutic response (Malucchi et al 2004).
Mechanisms of action
IFN β was ﬁ  rst tested for treatment of MS due to its antiviral 
property, as it was thought that the cause of the disease lay 
in a viral infection. Today, although viral infections are 
still considered and studied, at least as contributory factors, 
IFN β is regarded more as an immunomodulatory and 
antiproliferative treatment. Laboratory and clinical studies 
have in fact shown that it inhibits MS activity, acting on 
a variety of processes and molecular mediators within the 
immune system. IFN β modiﬁ  es the cytokine production in 
favor of the antinﬂ  ammatory subset, such as Il-10 and Il-4, 
inhibiting the release of proinﬂ  ammatory cytokines such 
as IFN β and tumor necrosis factor (Rothuizen et al 1999; 
Yong et al 1998). Other pharmacodinamic properties of IFN 
β include inhibition of T-cell activation, block of production 
of oxygen free radicals by mononuclear phagocytes, and 
reduced expression of major histocompatibility complex 
class II molecules, which in turn reduces self-antigen pre-
sentation in the CNS (Dhib-Jalbut 2002). A recent ex vivo 
and in vitro longitudinal study demonstrated that IFN β 
in its 1a form enhances CD4+ regulatory T cells activity 
(de Andres et al 2007).
Beneﬁ  cial effects of IFN β may also be due to to a protec-
tive role exerted at the level of the blood-brain barrier (BBB), 
by reducing the activity of metalloproteases that are respon-
sible for BBB disruption, and/or by preventing adhesion 
and subsequent migration of T-cells into the CNS (Galboiz 
et al 2001). In particular, it was demonstrated that IFN β 1a 
regulates the expression of serum and membrane-associated 
intercellular adhesion molecules (Giorelli et al 2002), and it 
is associated with up-regulation of vinculin and N-cadherin 
expression in brain endothelial cells (Harzheim et al 2004) 
restoring BBB disruption IFN β action-related.
Most of these pharmacodynamic properties depend on the 
interaction of IFN β with cell surface receptors (Wagstaff 
and Goa 1998). This interaction induces an intracellular 
signal cascade leading to the expression of IFN-stimulated 
genes, whose products such as neopterin, myxovirus resis-
tance protein A, β 2 microglobulin, and 2',5'-oligoadenylate 
synthetase, besides carrying out the effect of IFN, have also 
been studied and proposed as a tool to monitor the drug 
activity, and potentially the biological response to treatment 
(Bertolotto et al 2001).
However controversial the deﬁ  nition of IFNs β as disease-
modifying drugs may be, recent experimental studies have 
proposed a novel and neuroprotective mechanism of action 
for IFN β. The survival of retinal ganglion cells in the animal 
model MS, the experimental autoimmune encephalomyeli-
tis, was enhanced by treatment with IFN β 1a (Sättler et al 
2006). In addition, another study proved that IFN β stimulates 
the secretion of nerve growth factors by endothelial cells 
(Biernacki et al 2005). This axon protective effect was related 
to the antinﬂ  ammatory properties of the drug.Neuropsychiatric Disease and Treatment 2008:4(2) 323
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Pivotal clinical studies of interferon 
β 1a 22 or 44 µg s.c. t.i.w. (Rebif ®)
The PRISMS trial (Prevention of Relapses and Disability 
by Interferon β-1a Subcutaneously in Multiple Sclerosis) 
(PRISMS Study Group 1998; Li and Paty 1999) was the 
pivotal phase III trial that assessed efﬁ  cacy of IFN β 1a 22 
and 44 µg s.c. t.i.w. in RR MS patients. The study was a 
randomized, double-blind, placebo-controlled, clinical trial, 
meeting class I evidence, according to the rating of evidence 
classiﬁ  cation scheme of the AAN.
The EVIDENCE trial (EVidence of Interferon Dose-
response: European North American Comparative Efﬁ  cacy) 
(Panitch et al 2002) was a randomized, controlled, assessor-
blinded, parallel-group study, fulﬁ  lling as well the AAN 
criteria for class I data. It reported evidence for the best 
beneﬁ  t-to-risk ratio of higher doses and higher frequency 
of administration of IFN β 1-a 44 µg s.c. t.i.w. compared to 
IFN β 1a 30 µg i.m. q.w., and led to the approval of the drug 
in the United States.
PRISMS trial
In the PRISMS study (PRISMS Study Group 1998; Li and 
Paty 1999) 560 RRMS patients with an expanded disabil-
ity status scale (EDSS) (Kurtzke 1983) score   5.0 were 
randomized to 1 of 3 treatment arms (IFN β 1a s.c. t.i.w., 
either at dosages of 22 µg or 44 µg, or placebo). Patients 
with a disease duration   1 year were included in the study, 
providing they had had at least 2 relapses during the 2 years 
before enrolment. 22 centers from 9 different countries took 
part to the study. 189 patients were randomized to the lower 
dose (22 µg), 184 to the higher dose (44 µg) of IFN β 1a s.c. 
t.i.w., and 187 patients to placebo. Study groups were well 
balanced for patients’ characteristics at baseline. Primary 
analysis was as intention-to-treat study population.
The primary endpoint in the PRISMS trial was the clinical 
relapse rate over 2 years. Secondary endpoints consisted of 
other relapse rate parameters (time to ﬁ  rst relapse, percentage 
of patients remaining relapse free, relapse severity, steroid 
use, and hospitalization) and MRI attack rate measured by 
median number of T2 active lesions and volume of white 
matter disease seen on T2-weighted MRI. Additional second-
ary outcome measures included time to sustained disability 
progression (conﬁ  rmed after three months), ﬁ  ndings on an 
ambulation index and an arm-function index.
Only 10 patients in the placebo group and 17 patients in 
the treatment group were lost to the follow-up. The study 
demonstrated a beneﬁ  cial effect for all major outcomes with 
either drug dose regimen. The relapse rate in both IFN β 1a 
22 µg and 44 µg groups were signiﬁ  cantly reduced compared 
to the placebo group (1.82 and 1.73 respectively for treatment 
groups versus 2.56 in the placebo group, p   0.005). A 27% 
(p   0.05) and a 32% (p   0.005) reduction in relapse rate 
was achieved in the 22 µg group and in the 44 µg group, 
respectively, compared with the placebo group. The median 
time to ﬁ  rst relapse was signiﬁ  cantly delayed by 3 months 
in the lower dosage group, and by 5 months in the higher 
dose treatment group versus placebo (statistical signiﬁ  cance 
not reported). A signiﬁ  cant reduction in moderate to severe 
types of relapses (p   0.005) and in corticosteroids courses 
(p   0.05 for the 22 µg group; p   0.005 for the 44 µg group) 
was also observed in the active arms compared to placebo. 
Number of hospitalizations signiﬁ  cantly decreased in the 
44 µg group (p   0.005 versus placebo).
Median MRI lesion load signiﬁ  cantly decreased in both 
the active treatment groups (–1.2% in the 22 µg group 
and –3.85% in the 44 µg group; p   0.0001), whereas it 
increased (+ 10.9%) in the placebo group. In addition, T2 
active lesion number was reduced in the active treatment 
groups (–67% for the 22 µg, –78% for the 44 µg; p   0.0001) 
compared to placebo. The decrease was more evident in the 
higher dosage group compared to the lower dosage group 
(p   0.0003), suggesting a likely dose-response effect.
Besides clinical or paraclinical measures of disease activ-
ity, some measures of disability progression were included 
in the PRISMS trial. The study showed that time to ﬁ  rst 
progression of disability measured by the EDSS for the 25th 
percentile of patients was 18.5 months in the IFN β 1a 22 µg 
group and 21.3 months in the IFN β 1a 44 µg group, com-
pared with 11.9 months in the placebo group (p   0.05).
It is worth saying that this kind of ﬁ  xed disability assess-
ment is not free from misinterpretation, as it does not take 
into account long term ﬂ  uctuations or relapses persisting for 
more than 3 months. In addition, according to natural history 
of MS, disability take place over the course of many years 
(Weinshenker et al 1991), while the trial lasted a relatively 
short time. The EDSS scale, used for detecting disease 
progression, has also been questioned for its non linearity 
(Cohen et al 1993), lack of representation of all facets of 
functional impairment, insensitivity to changes, and other 
pitfalls such as the poor inter-rater and test-retest reliabilities 
(Noseworthy et al 1990; Rudick et al 1996), especially at 
the lower echelons of the scale (range typical of patients 
included in the trial). In order to address the doubts risen 
about the protective effect of IFN β 1a 22 and 44 µg s.c. 
t.i.w. on disability accrual, further evaluation was carried 
out on the EDSS scores by a post-hoc analysis of patients Neuropsychiatric Disease and Treatment 2008:4(2) 324
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included in the PRISMS trial. The area under disability/
time curves was calculated to quantify in-trial changes, 
which, although potentially advantageous, proved lack of 
information on direction of changes (Liu and Blumhardt 
1999). In another post-hoc analysis, disease trend analysis 
and categorical classiﬁ  cation using serial EDSS scores (Liu 
and Blumhardt, 2002) conﬁ  rmed that IFN β 1a 22 and 44 
µg s.c. t.i.w. increased the proportion of patients with a 
stable course and reduced those with prolonged disabling 
deterioration. Although these calculations were still based 
on EDSS scores, and inherently incorporated the potential 
disadvantages of the scale, they reduced the errors associated 
with conventional conﬁ  rmed progression deﬁ  nition. They 
also revealed that baseline disease duration and EDSS levels 
were predictive of the disability trends, and that the treatment 
effect was more signiﬁ  cant for subjects with entry EDSS of 
over 3.5 and shorter disease duration. Further evidence from 
later studies corroborated the results of the PRISMS trial, 
as they validated the predictive role of short-term outcome 
variables used in the trial on subsequent long-term disability 
accumulation.
The relationship between relapses and disease progres-
sion is not well deﬁ  ned: Confavreux et al (2000) reported 
that relapses do not signiﬁ  cantly inﬂ  uence the progression 
of irreversible disability while other authors, analyzing 
a large database from a combination of previous trials, 
concluded that MS exacerbations produce a measurable 
and sustained effect on disability (Lublin et al 2003). Early 
population-based natural history studies (Weinshenker et al 
1989; Weinshenker 1995; Wingerchuk and Weinshenker 
1999) have demonstrated a relationship between early clini-
cal relapse rate and subsequent development of disability, 
thus supporting the hypothesis that a drug that lessens the 
number of relapses can positively affect MS clinical course 
over the years.
Among the paraclinical MRI markers of disease activ-
ity used in the PRISMS trial, on which IFN β 1a 22 and 
44 µg s.c. t.i.w. had proved beneﬁ  cial effect, disturbance of 
the blood – brain barrier, as detected by MRI gadolinium 
enhancement, was shown to be a predictor of the occurrence 
of relapses, but not a strong predictor of development of 
cumulative impairment or disability (Kappos et al 1999). On 
the other hand, some authors have recently demonstrated in 
a long-term longitudinal study (13 years) that baseline T2 
lesions volume in RR MS patients strongly correlated with 
brain tissue loss and brain integrity, and that changes in T2 
lesion volume over the ﬁ  rst 2 years correlated with clinical 
disease severity (Rudick et al 2006). Those results support 
the therapeutic beneﬁ  t of IFN β 1a 22 and 44 µg s.c. t.i.w., 
as treatment is capable of acting on a MRI surrogate marker 
of disease linked to long-term progression.
EVIDENCE trial
Some pharmacological and clinical studies have postulated 
the hypothesis of a dosage-frequency dependent response to 
IFN β. Whereas pharmacodynamic measurements of IFN β 
showed a greater activity after a single high dose (Williams 
and Witt 1998; Stürzebecher et al 1999), studies in healthy 
volunteers demonstrated a sustained response to IFN β 1a 
when administered 3 times a week rather than once weekly 
(Rothuizen et al 1999).
Clinical studies indicated that IFN beta 1b at the dose of 
8 million international units (MIU) was superior to 1.8 MIU 
on both clinical and MRI endpoints (The IFNB Multiple 
Sclerosis Study Group 1993). Furthermore, the PRISMS 
trial showed an overall better outcome for IFN β 1a 44 µg 
vs IFN β 1a 22 µg regimen. In addition, the limited clinical 
effect of IFN β 1a 22 or 44 µg s.c. q.w. (The Once Weekly 
Interferon for MS Study Group 1999) contrasted with the 
positive results obtained in the PRISMS trial, where the same 
drug was given t.i.w.
This experimental and clinical evidence prompted the 
EVIDENCE trial (Panitch et al 2002), with the aim to prove 
the superiority of higher dosages-higher frequency of sub-
cutaneous preparation in a head-to-head comparison of IFN 
β 1a 44 µg s.c. t.i.w. with IFN β 1a 30 µg i.m. q.w. In the 
study, 677 patients with RRMS and at least 2 exacerbations 
of MS in the prior 2 years, and EDSS scores of 0–5.5, were 
enrolled at 56 centers (15 in Europe, 5 in Canada, and 36 in 
the United States). Following randomization, 338 patients 
received IFN β 1a i.m. at the dose of 30 µg q.w. while 339 
were given IFN β 1a at the dose of 44 µg s.c. t.i.w. Treat-
ment lasted 48 weeks.
The primary endpoints were the proportion of patients 
remaining relapse free, and an MRI outcome measure which 
consisted of the number of combined unique (CU) active 
lesions per patient per scan, a measure of both active T2 and 
T1 gadolinium (Gd) enhancing lesions. A CU lesion was 
deﬁ  ned as an active lesion on T1 post-Gd or T2 sequences, 
or both, avoiding double counting; an active T2 lesion was 
deﬁ  ned as a new or enlarging lesion, or a lesion reappear-
ing at a site of previous lesion resolution. Secondary and 
tertiary clinical outcome measures included relapse rate, 
relapse severity, use of steroids for relapses, and time to 
ﬁ  rst relapse and disability progression, deﬁ  ned by one point 
increase on the EDSS scale conﬁ  rmed at a visit 3 or 6 months Neuropsychiatric Disease and Treatment 2008:4(2) 325
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later. Secondary MRI outcome measures included number 
of T2 and T1 lesions per patient per scan, the proportion of 
active scans (T2, T1, and CU) per patient, and the proportion 
of patients in whom active scans (T2, T1, and CU) either 
occurred or did not occur during the initial 24 weeks of the 
trial. At week 48 only T2 lesions were counted and measured, 
as Gd was not administered.
There were no signiﬁ  cant differences in baseline char-
acteristics between treatment groups. The results over the 
initial 24 weeks of treatment showed that 75% of patients 
in the 44 µg s.c. t.i.w. group and 63% of those in the 30 µg 
i.m. q.w. group remained relapse free. The odds ratio (OR), 
adjusted for center, was 1.9 (p   0.0005), indicating a rela-
tive increase of 90% in the odds of remaining relapse free 
during the ﬁ  rst 24 weeks of therapy for patients receiving 
44 µg s.c. t.i.w. compared with those receiving 30 µg i.m. 
q.w. The response was maintained over 48 weeks of treat-
ment albeit less marked, as 62% of patients in the 44 µg s.c. 
t.i.w. group and 52% of those in the 30 µg i.m. q.w. group 
remained relapse free. The OR, adjusted for center, was 1.5 
(p   0.009), indicating a relative increase of 50% in the odds 
of remaining relapse free for patients receiving 44 µg s.c. 
t.i.w. compared with those given 30 µg i.m. q.w.
As far as MRI primary outcome is concerned, patients 
treated with IFN β 1a 44 µg s.c. t.i.w. had fewer CU, T1, 
and T2 active lesions per MRI scan compared with those 
treated with 30 µg i.m. q.w. at week 24 (p   0.0001 for all 
activity measures). Outcome data on other relapse-related 
measures also favored 44 µg s.c. t.i.w. treatment. The time 
to ﬁ  rst relapse was prolonged over the course of the study 
for patients treated with 44 µg s.c. t.i.w. (hazard ratio 0.70; 
p   0.003). Relapse rates were 0.29 in the 44 µg s.c. t.i.w. 
group and 0.40 in the 30 µg i.m. q.w. group at 24 weeks, 
with a 27% relative difference (p   0.022), and continued 
to be lower at 48 weeks, although the difference was less 
pronounced: 0.54 in the 44 µg s.c. t.i.w. group compared 
with 0.64 in the 30 µg i.m. q.w. group, with a 16% relative 
difference (p   0.093). The mean rate of steroid use for 
relapses was lower for the 44 µg s.c. t.i.w. group compared 
to the 30 µg i.m. q.w. group (p   0.017). There was a trend 
toward reduction of risk progression in the 44 µg s.c. t.i.w. 
group compared with the 30 µg i.m. q.w. group.
Additional MRI outcomes conﬁ  rmed the superiority of 
the higher dose-higher frequency preparation. The mean 
number of active scans per patient was also reduced in 
patients receiving 44 µg compared with those receiving 
30 µg i.m. q.w. Only the number of T2-active lesions after 
48 weeks could be calculated by comparing the baseline and 
week 48 scans, as Gd was not administered. Differences 
between treatment groups still favored the 44 µg s.c. t.i.w. 
patients for mean number of T2 lesions per patient per scan 
(36% relative reduction), proportion of T2-active scans 
(38% relative reduction), and proportion of patients with 
no T2 active lesions over 48 weeks (32% relative increase) 
(p   0.001 for all comparisons).
In summary, the trial provided evidence of a clinical 
superior efﬁ  cacy of IFN β 1a 44 µg s.c. t.i.w.on IFN β 1a 
30 µg i.m. q.w. in RRMS patients. However, which aspect of 
the different IFN β preparations was more relevant remained 
unsolved: total weekly dose, frequency of administration, 
or method of administration. Results of EVIDENCE trial 
were in agreement with another study that compared IFN 
β 1-b 8MIU s.c q.o.d. with IFN β 1a 30 µg i.m. q.w., the 
Independent Comparison of Interferon Study (Durelli et al 
2002). Compared to the latter, the EVIDENCE trial has been 
rated as class I evidence on the AAN rating scale, as assessor 
blinding was guaranteed.
Theoretically, a head-to-head comparison of disease 
modifying drugs in MS would require a randomized, double-
blind, placebo-controlled trial with a long-term follow-up. 
However, this study design would not meet ethics’ commit-
tee approval as it would imply placebo use for long time, 
while established therapy could be offered to the patients, 
and would be unpractical for the different route of admin-
istration and maintenance of blindness for injection-related 
side effects. Hence, assessor-blind design represents a valid 
alternative, as it assures reliability of study results.
PRISMS study extensions
The PRISMS study was further extended to 4 years 
(PRISMS-4), and patients originally randomized to placebo 
were re-randomized to either IFN β 1a 22 or 44 µg s.c. t.i.w. 
(PRISMS Study Group, University of British Columbia MS/
MRI Analysis Group 2001). The study provided evidence 
for a sustained efﬁ  cacy of IFN β 1a 22 and 44 µg s.c. t.i.w. 
over the extended time on both clinical (relapse rate and time 
to disability progression) and MRI outcomes (MRI activity 
and lesion burden), and a dose-dependent drug response. In 
addition, outcomes were consistently better for patients who 
continued the active treatment compared to the cross-over 
group, suggesting the importance of an early treatment.
Additional evidence comes from the long-term follow-up 
(LTFU) study that included patients in the original PRISMS 
trial (Kappos et al 2006). Assessments included clinical and 
MRI exams of patients who had been enrolled in the PRISMS 
study, coinciding as close as possible with the seventh or Neuropsychiatric Disease and Treatment 2008:4(2) 326
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eighth anniversary of enrollment. To date, this is one of the 
longest follow-up trial of a pivotal phase III study published. 
At the LTFU visit, EDSS scores along with documentation 
of ongoing relapses and clinical data from the ﬁ  nal neuro-
logical assessment of PRISMS-4 were reviewed. PD/T2 
weighted scans were performed for blinded measurement 
of lesion volume. Brain atrophy was also analysed as brain 
parenchimal volume derived from the intracranial volume 
by subtracting the CSF volume. Out of the initial 560 patient 
cohort, 382 patients were re-evaluated at LTFU, and 72% 
of attending patients were still receiving IFN β 1a at one of 
the two dose regimens. A total of 35% of patients receiving 
IFN β 1a s.c. t.i.w. had converted from one dose to the other, 
with the majority switching from 22 µg to 44 µg; the ﬁ  gure 
was probably inﬂ  uenced by local treatment guidelines and 
reimbursement practice in the different countries participat-
ing in the trial. One of the most interesting results of the study 
was that the longest time to reach a conﬁ  rmed progression 
was detected in patients originally randomized to 44 µg, 
compared to patients who were crossed over to treatment after 
2 years of placebo (late treatment group, LTG). Patients were 
more likely to be relapse free if they started on the higher 
dose, and both relapse rate and T2 lesion accumulation were 
similarly lower in the 44 µg group compared with the LTG. 
Study results conﬁ  rmed what had already emerged at 4 years 
extension, ie, higher drug dose and earlier treatment were the 
key issues to achieve a better outcome.
Post-marketing clinical studies 
of interferon β 1a 22 and 44 µg s.c. 
t.i.w. (Rebif ®)
Additional evidence on efﬁ  cacy of IFN β 1a 22 and 44 µg 
s.c. t.i.w. in a less strictly selected MS patients populations 
can be derived from Phase IV studies, as well as from retro-
spective chart reviews. Overall, these studies adopted wider 
inclusion/exclusion criteria than pivotal trials, but more 
adherent to clinical practice settings. Most studies were 
conducted with the aim of detecting differences between 
available disease-modifying drugs in MS that were not shown 
in randomized, controlled clinical trials. Comparison of study 
results with those from pivotal trials is indeed precluded by 
the different methodologies they employed. We reviewed 9 
open-label, post-marketing, observational, controlled studies 
that compared the relative long-term efﬁ  cacy and tolerability 
of various IFNs β in the treatment of RRMS. We included in 
our review only published studies that had a follow-up of at 
least 2 years, a group of patients on INF β 1a s.c. t.i.w. and 
included more than 15 patients per treatment group.
Overall, 9 studies were considered (Paolillo et al 2002; 
Haas et al 2005; Milanese et al 2005; Rio et al 2005; Trojano 
et al 2005; Bonavita et al 2006; Etemadifar et al 2006; 
Kock-Henriksen et al 2006; Limmroth et al 2007). Details 
of these studies are provided in Tables 1 which summarizes 
trial design, number of patients, main clinical outcomes, 
and results. A large variability among study characteristics 
precludes any comparison of the effects of INF β 1a s.c. 
t.i.w.. Indeed, the number of patients who reached a certain 
follow-up and administered dose of IFN β 1a s.c. t.i.w. were 
sometimes not speciﬁ  ed or differed among studies, making 
impossible to compute a cumulative patient-year treatment 
number for each IFN β 1a s.c. t.i.w. formulation. Patients 
selection, sample size, missing data, clinical outcomes, and 
other issues signiﬁ  cantly impair the actual reliability of stud-
ies results. Lack of randomization, variation in follow-up 
duration and changes of drug treatments contribute to limit 
the assessment of therapeutic response and largely bias the 
results. An higher number of patients receiving IFN β 1a 
30 µg i.m. q.w. and IFN β 1b 8 MIU s.c q.o.d. than IFN β 
1a 22 and 44 µg s.c. t.i.w. was generally reported, in rela-
tion to the earlier availability of these formulations at some 
study sites.
Most of these studies showed no differences in term 
of efﬁ  cacy among the different IFNs β preparations and 
dose regimens. Others detected a favorable effect of higher 
frequency and higher doses on clinical outcomes. IFN β 1a 
44 µg s.c. t.i.w. resulted less effective than other IFNs β in 
one single study (Limmroth et al 2007). In this retrospective, 
controlled, observational trial, including one of the largest 
case cohorts, IFN β 1a 44 µg s.c. t.i.w. was used in a signiﬁ  -
cantly higher number of patients than other treatments, indi-
cating that it was likely substitute for a prior drug in patients 
with disease progression. Hence, patients in IFN β 1a 44 µg 
s.c. t.i.w. could have had a higher disease activity, and thus 
a poor therapeutic response. As most studies had a follow-
up of 2 years it cannot be excluded that comparable efﬁ  cacy 
among different IFNs β preparations had not been inﬂ  uenced 
by development of neutralizing antibodies (NAbs), unlikely 
in this relative short timeframe (Vartanian et al 2004).
Only few of these studies included paraclinical measures 
of response, and often in a subgroup of patients, further 
limiting any exhaustive conclusion. However, overall results 
from these ancillary studies matched the results observed 
in randomized-controlled trials. Indeed reviews and meta-
analysis of disease modifying drugs in MS have conﬁ  rmed 
the clinical validity and usefulness of open label trials and 
their substantial consistency with the results of pivotal trials Neuropsychiatric Disease and Treatment 2008:4(2) 327
Efﬁ  cacy of Rebif® in multiple sclerosis
 
 
T
a
b
l
e
 
1
 
P
o
s
t
-
m
a
r
k
e
t
i
n
g
 
s
t
u
d
i
e
s
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
S
t
u
d
y
F
U
 
y
e
a
r
s
C
l
i
n
i
c
a
l
 
o
u
t
c
o
m
e
s
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
t
h
e
 
s
t
u
d
y
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
a
n
d
 
t
r
e
a
t
m
e
n
t
B
o
n
a
v
i
t
a
 
e
t
 
a
l
 
2
0
0
6
2
–
 
R
e
d
u
c
t
i
o
n
 
i
n
 
r
e
l
a
p
s
e
 
r
a
t
e
–
 
 
O
R
 
f
o
r
 
r
e
m
a
i
n
i
n
g
 
r
e
l
a
p
s
e
 
f
r
e
e
–
 
C
h
a
n
g
e
 
o
f
 
E
D
S
S
 
s
c
o
r
e
–
 
 
O
R
 
f
o
r
 
r
e
m
a
i
n
i
n
g
 
p
r
o
g
r
e
s
s
i
o
n
 
f
r
e
e
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
-
t
i
v
e
5
8
 
A
,
 
4
2
 
B
,
 
4
8
 
R
 
2
2
,
 
6
7
 
R
 
4
4
R
e
s
u
l
t
s
 
•
 
P
a
t
i
e
n
t
s
 
i
n
 
R
 
4
4
 
m
o
r
e
 
l
i
k
e
l
y
 
t
o
 
r
e
m
a
i
n
 
f
r
e
e
 
f
r
o
m
 
r
e
l
a
p
s
e
s
 
O
R
 
=
 
2
.
2
3
E
t
e
m
a
d
i
f
a
r
 
e
t
 
a
l
 
2
0
0
6
2
–
 
M
e
a
n
 
r
e
l
a
p
s
e
 
r
a
t
e
–
 
 
P
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
m
a
i
n
-
i
n
g
 
r
e
l
a
p
s
e
 
f
r
e
e
 
a
f
t
e
r
 
2
 
y
e
a
r
s
–
 
C
h
a
n
g
e
 
o
f
 
E
D
S
S
 
s
c
o
r
e
P
r
o
s
p
e
c
t
i
v
e
,
 
r
a
n
d
o
m
i
z
e
d
,
 
a
s
s
e
s
s
o
r
-
b
l
i
n
d
e
d
3
0
 
A
3
0
 
B
3
0
 
R
 
4
4
R
e
s
u
l
t
s
 
•
 
M
e
a
n
 
r
e
l
a
p
s
e
 
r
a
t
e
 
d
e
c
r
e
a
s
e
d
 
i
n
 
a
l
l
 
g
r
o
u
p
s
 
(
l
o
w
e
r
 
i
n
 
B
 
a
n
d
 
R
 
4
4
 
g
r
o
u
p
s
 
c
o
m
p
a
r
e
d
 
t
o
 
A
 
g
r
o
u
p
)
 
•
 
P
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
m
a
i
n
i
n
g
 
r
e
l
a
p
s
e
 
f
r
e
e
 
a
f
t
e
r
 
2
 
y
e
a
r
s
 
(
A
 
2
0
%
,
 
B
 
4
3
%
,
 
R
 
4
4
 
5
6
%
)
 
•
 
E
D
S
S
 
c
h
a
n
g
e
 
(
A
 
s
t
a
b
l
e
,
 
B
 
0
.
7
 
U
 
r
e
d
u
c
t
i
o
n
,
 
R
 
0
.
3
 
U
 
r
e
d
u
c
t
i
o
n
)
H
a
a
s
 
e
t
 
a
l
 
2
0
0
5
2
–
 
R
e
l
a
p
s
e
 
r
a
t
e
–
 
 
n
u
m
b
e
r
 
o
f
 
r
e
l
a
p
s
e
-
f
r
e
e
 
p
a
t
i
e
n
t
s
–
 
m
e
a
n
 
E
D
S
S
 
c
h
a
n
g
e
–
 
 
p
r
o
g
r
e
s
s
i
o
n
 
r
a
t
e
 
(
E
D
S
S
 
c
h
a
n
g
e
 
 
 
1
)
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
-
t
i
v
e
A
,
B
,
R
 
2
2
,
C
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
r
e
a
c
h
e
d
 
2
 
y
e
a
r
 
F
U
 
p
e
r
 
e
a
c
h
 
g
r
o
u
p
 
i
s
 
n
o
t
 
s
p
e
c
i
ﬁ
 
e
d
R
e
s
u
l
t
s
 
•
 
A
l
l
 
g
r
o
u
p
s
 
s
h
o
w
e
d
 
s
u
s
t
a
i
n
e
d
 
r
e
d
u
c
t
i
o
n
 
o
f
 
r
e
l
a
p
s
e
 
r
a
t
e
,
 
h
i
g
h
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
r
e
l
a
p
s
e
-
f
r
e
e
 
p
a
t
i
e
n
t
s
 
a
n
d
 
r
e
d
u
c
e
d
 
p
r
o
g
r
e
s
s
i
o
n
 
i
n
d
e
x
 
•
 
 
N
o
 
s
u
p
e
r
i
o
r
i
t
y
 
o
f
 
o
n
e
 
o
f
 
t
h
e
 
I
N
F
β
 
p
r
e
p
a
r
a
t
i
o
n
s
 
e
x
c
e
p
t
 
f
o
r
 
h
i
g
h
e
s
t
 
r
e
l
a
p
s
e
-
r
a
t
e
 
d
e
c
l
i
n
e
 
a
f
t
e
r
 
2
4
 
m
o
n
t
h
s
 
i
n
 
t
h
e
 
C
 
g
r
o
u
p
 
a
n
d
 
p
r
o
g
r
e
s
s
i
o
n
 
i
n
d
e
x
 
s
i
g
n
i
ﬁ
 
c
a
n
t
l
y
 
l
o
w
e
r
 
i
n
 
R
 
2
2
 
a
n
d
 
C
 
g
r
o
u
p
s
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
B
 
g
r
o
u
p
K
o
c
k
-
H
e
n
r
i
k
s
e
n
 
e
t
 
a
l
 
2
0
0
6
2
–
 
a
n
n
u
a
l
i
z
e
d
 
r
e
l
a
p
s
e
 
r
a
t
e
–
 
t
i
m
e
 
t
o
 
ﬁ
 
r
s
t
 
r
e
l
a
p
s
e
–
 
 
t
i
m
e
 
t
o
 
s
u
s
t
a
i
n
e
d
 
p
r
o
g
r
e
s
s
i
o
n
O
p
e
n
-
l
a
b
e
l
,
 
p
r
o
s
p
e
c
t
i
v
e
,
 
r
a
n
d
o
m
i
z
e
d
1
8
8
 
B
1
1
0
 
R
 
2
2
R
e
s
u
l
t
s
 
•
 
N
o
 
s
u
p
e
r
i
o
r
i
t
y
 
o
f
 
o
n
e
 
o
f
 
t
h
e
 
I
N
F
β
 
p
r
e
p
a
r
a
t
i
o
n
s
 
i
n
 
a
n
y
 
o
f
 
c
l
i
n
i
c
a
l
 
o
u
t
c
o
m
e
s
L
i
m
m
r
o
t
h
 
V
 
e
t
 
a
l
 
2
0
0
7
2
–
 
 
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
E
D
S
S
 
s
c
o
r
e
–
 
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
p
a
t
i
e
n
t
s
 
(
 
1
.
0
 
E
D
S
S
 
s
c
o
r
e
)
–
 
a
n
n
u
a
l
i
z
e
d
 
r
e
l
a
p
s
e
 
r
a
t
e
–
 
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
r
e
l
a
p
s
e
-
f
r
e
e
 
p
a
t
i
e
n
t
s
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
-
t
i
v
e
A
s
 
i
n
i
t
i
a
l
 
t
h
e
r
a
p
y
A
 
1
4
6
9
,
 
B
 
1
4
8
4
,
 
R
2
2
 
7
8
4
,
 
R
4
4
 
2
5
4
A
s
 
F
U
 
t
h
e
r
a
p
y
A
 
2
2
4
,
 
B
 
1
8
2
,
 
R
 
2
2
 
1
2
6
 
R
 
4
4
 
1
3
0
(
a
f
t
e
r
 
a
n
o
t
h
e
r
 
D
M
T
 
t
h
e
y
 
h
a
d
 
r
e
c
e
i
v
e
d
 
f
o
r
 
l
e
s
s
 
t
h
a
n
 
2
 
y
e
a
r
s
)
(
C
o
n
t
i
n
u
e
d
)Neuropsychiatric Disease and Treatment 2008:4(2) 328
Manfredonia et al
T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
F
U
 
y
e
a
r
s
C
l
i
n
i
c
a
l
 
o
u
t
c
o
m
e
s
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
t
h
e
 
s
t
u
d
y
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
a
n
d
 
t
r
e
a
t
m
e
n
t
R
e
s
u
l
t
s
 
•
 
 
N
o
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
a
m
o
n
g
 
I
F
N
s
 
β
 
w
h
e
n
 
u
s
e
d
 
a
s
 
i
n
i
t
i
a
l
 
o
r
 
F
U
 
t
h
e
r
a
p
y
 
o
n
 
a
l
m
o
s
t
 
a
l
l
 
o
u
t
c
o
m
e
 
v
a
r
i
a
b
l
e
s
 
(
p
e
r
c
e
n
t
a
g
e
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
p
a
t
i
e
n
t
s
 
l
o
w
e
r
 
i
n
 
R
 
4
4
 
g
r
o
u
p
,
 
b
u
t
 
R
 
4
4
 
w
a
s
 
u
s
e
d
 
m
o
r
e
 
o
f
t
e
n
 
a
s
 
F
U
 
t
r
e
a
t
m
e
n
t
,
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
a
 
l
i
k
e
l
y
 
h
i
g
h
e
r
 
d
i
s
e
a
s
e
 
a
c
t
i
v
i
t
y
)
M
i
l
a
n
e
s
e
 
e
t
 
a
l
 
2
0
0
5
1
–
3
–
 
 
a
n
n
u
a
l
 
r
e
l
a
p
s
e
 
f
r
e
q
u
e
n
c
y
 
c
o
m
-
p
a
r
e
d
 
t
o
 
p
r
e
-
t
r
e
a
t
m
e
n
t
 
v
a
l
u
e
s
–
 
E
D
S
S
 
c
h
a
n
g
e
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
t
i
v
e
1
1
5
 
A
,
 
6
7
 
B
,
 
4
5
 
R
2
2
,
 
1
8
 
R
4
4
,
 
4
9
 
C
R
e
s
u
l
t
s
 
•
 
 
A
n
n
u
a
l
 
r
e
l
a
p
s
e
 
f
r
e
q
u
e
n
c
y
 
c
o
m
p
a
r
e
d
 
t
o
 
p
r
e
-
t
r
e
a
t
m
e
n
t
 
v
a
l
u
e
s
 
d
e
c
r
e
a
s
e
d
 
b
y
 
6
3
%
,
 
6
7
%
,
 
4
0
%
,
 
5
8
%
,
 
a
n
d
 
3
2
%
 
i
n
 
A
,
 
B
,
 
R
2
2
,
 
R
4
4
 
a
n
d
 
C
 
a
f
t
e
r
 
1
 
y
e
a
r
 
a
n
d
 
c
o
n
t
i
n
u
e
d
 
t
o
 
d
e
c
r
e
a
s
e
 
i
n
 
t
h
e
 
s
u
b
s
e
q
u
e
n
t
 
y
e
a
r
s
 
(
8
1
%
,
 
8
6
%
,
 
7
9
%
,
 
7
9
%
,
 
a
n
d
 
7
6
%
 
r
e
s
p
e
c
t
i
v
e
l
y
 
a
f
t
e
r
 
5
 
y
e
a
r
s
)
 
•
 
E
D
S
S
 
d
o
e
s
 
n
o
t
 
c
o
n
s
i
s
t
e
n
t
l
y
 
c
h
a
n
g
e
 
i
n
 
a
n
y
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
P
a
o
l
i
l
l
o
 
e
t
 
a
l
 
2
0
0
2
6
–
 
 
M
e
a
n
 
a
n
n
u
a
l
 
r
e
l
a
p
s
e
 
r
a
t
e
 
c
o
m
-
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
2
-
y
e
a
r
 
p
e
r
i
o
d
 
b
e
f
o
r
e
 
t
r
e
a
t
m
e
n
t
–
 
 
s
u
s
t
a
i
n
e
d
 
p
r
o
g
r
e
s
s
i
o
n
 
d
e
ﬁ
 
n
e
d
 
a
s
 
a
n
 
i
n
c
r
e
a
s
e
 
o
f
 
a
t
 
l
e
a
s
t
 
1
 
p
o
i
n
t
 
i
n
 
E
D
S
S
 
s
c
o
r
e
s
 
6
 
m
o
n
t
h
s
 
a
p
a
r
t
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
-
t
i
v
e
6
8
 
p
a
t
i
e
n
t
s
A
l
l
 
r
e
c
e
i
v
e
d
 
R
 
f
o
r
 
t
h
e
 
ﬁ
 
r
s
t
 
2
 
y
e
a
r
s
 
a
t
 
d
i
f
f
e
r
e
n
t
 
d
o
s
e
s
–
 
1
6
 
c
o
n
t
i
n
u
e
d
 
w
i
t
h
 
R
 
3
3
 
µ
g
 
t
.
i
.
w
–
 
5
2
 
c
o
n
t
i
n
u
e
d
 
w
i
t
h
 
B
–
 
1
1
 
d
r
o
p
-
o
u
t
s
R
e
s
u
l
t
s
 
•
 
M
e
a
n
 
a
n
n
u
a
l
 
r
e
l
a
p
s
e
 
r
a
t
e
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
2
 
y
e
a
r
 
p
e
r
i
o
d
 
b
e
f
o
r
e
 
t
r
e
a
t
m
e
n
t
 
r
e
d
u
c
e
d
 
(
6
8
.
6
%
)
 
•
 
S
u
s
t
a
i
n
e
d
 
p
r
o
g
r
e
s
s
i
o
n
:
6
0
%
 
o
f
 
p
a
t
i
e
n
t
s
 
r
e
m
a
i
n
 
s
t
a
b
l
e
 
o
r
 
i
m
p
r
o
v
e
d
R
ì
o
 
e
t
 
a
l
 
2
0
0
5
8
–
 
 
p
r
o
p
o
r
t
i
o
n
s
 
o
f
 
r
e
l
a
p
s
e
-
f
r
e
e
 
p
a
t
i
e
n
t
s
–
 
 
r
e
l
a
p
s
e
 
r
a
t
e
 
c
o
m
p
a
r
e
d
 
t
o
 
2
 
y
e
a
r
s
 
b
e
f
o
r
e
 
t
r
e
a
t
m
e
n
t
–
 
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
r
e
m
a
i
n
i
n
g
 
p
r
o
-
g
r
e
s
s
i
o
n
 
f
r
e
e
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
-
t
i
v
e
A
t
 
y
e
a
r
 
5
A
 
3
7
B
 
1
1
4
R
 
1
7
 
(
d
o
s
e
 
n
o
t
 
s
p
e
c
i
ﬁ
 
e
d
)
R
e
s
u
l
t
s
 
•
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
t
h
e
 
d
i
f
f
e
r
e
n
t
 
p
r
o
d
u
c
t
s
 
w
e
r
e
 
o
b
s
e
r
v
e
d
T
r
o
j
a
n
o
 
e
t
 
a
l
 
2
0
0
5
3
–
6
–
 
R
e
l
a
p
s
e
 
r
a
t
e
–
 
E
D
S
S
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
O
b
s
e
r
v
a
t
i
o
n
a
l
,
 
r
e
t
r
o
s
p
e
c
-
t
i
v
e
3
9
5
 
A
,
 
2
9
4
 
B
,
 
3
9
7
 
R
 
2
2
,
 
8
7
 
R
 
4
4
R
e
s
u
l
t
s
 
•
 
A
l
l
 
g
r
o
u
p
s
 
s
h
o
w
e
d
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
r
e
d
u
c
t
i
o
n
 
i
n
 
r
e
l
a
p
s
e
 
r
a
t
e
 
(
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
n
o
t
 
s
i
g
n
i
ﬁ
 
c
a
n
t
)
 
•
 
A
l
l
 
g
r
o
u
p
s
 
s
h
o
w
e
d
 
i
n
c
r
e
a
s
e
d
 
E
D
S
S
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
a
f
t
e
r
 
2
 
y
e
a
r
s
 
(
i
n
c
r
e
a
s
e
 
h
i
g
h
e
r
 
i
n
 
B
 
g
r
o
u
p
)
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
,
 
A
v
o
n
e
x
;
 
B
,
 
B
e
t
a
f
e
r
o
n
,
 
B
e
t
a
s
e
r
o
n
;
 
E
D
S
S
,
 
e
x
p
a
n
d
e
d
 
d
i
s
a
b
i
l
i
t
y
 
s
t
a
t
u
s
 
s
c
a
l
e
;
 
R
 
2
2
,
 
R
e
b
i
f
 
2
2
 
µ
g
,
 
R
 
4
4
 
R
e
b
i
f
 
4
4
 
µ
g
;
 
C
,
 
C
o
p
a
x
o
n
e
;
 
D
M
T
,
 
d
i
s
e
a
s
e
-
m
o
d
i
f
y
i
n
g
 
t
r
e
a
t
m
e
n
t
;
 
F
U
,
 
f
o
l
l
o
w
-
u
p
;
 
O
R
,
 
o
d
d
s
 
r
a
t
i
o
;
 
R
R
M
S
,
 
r
e
l
a
p
s
i
n
g
-
r
e
m
i
t
t
i
n
g
 
m
u
l
t
i
p
l
e
 
s
c
l
e
r
o
s
i
s
.Neuropsychiatric Disease and Treatment 2008:4(2) 329
Efﬁ  cacy of Rebif® in multiple sclerosis
(Benson and Hartz 2000; Concato et al 2000; Juni et al 2001). 
The extent of relapse rate reduction in these post-marketing 
trials was generally greater than that reported in pivotal tri-
als. This effect was likely related to the selective exclusion 
from the analysis of non-responder patients, and hence an 
overestimation of beneﬁ  t. Interestingly, most of these studies 
conﬁ  rmed beside a relapse rate reduction, a favorable effect 
of IFN β 1a 22 or 44 µg s.c. t.i.w. on disability measures, 
foreseeing a protective role on disease progression, in accor-
dance with the results of long-term analysis conducted by 
Kappos in the 7–8 years long-term follow-up study of the 
PRISMS cohort.
Besides improving our knowledge and validating the 
results of pivotal trials in clinical practice it is important to 
mention that some post-marketing studies have also explored 
the possible extension of INFs β indication in early-onset MS 
for which no treatment is currently approved. Few studies 
have assessed safety and tolerability of IFN β 1a 22 or 44 µg 
s.c. t.i.w. in this particular subtype of MS patients (Pohl et al 
2005; Tenembaum et al 2006) and provided efﬁ  cacy evidences 
(Ghezzi et al 2005; Ghezzi et al 2007), although limited by the 
absence of a randomized double blind control design, and the 
treatment is now being offered off-label in many MS centers 
while waiting for more methodologically robust trials.
ETOMS trial
Recent randomized controlled trials have provided evidence 
on efﬁ  cacy of INF β 1a 22 and 44 µg s.c. t.i.w. in other MS 
subtypes.The drug was tested in a cohort of patients with 
CIS likely to develop MS (Comi et al 2001), and in SPMS 
patients (SPECTRIMS Study Group 2001). The rationale for 
treating patients earlier in the course of the disease is based 
upon several evidences. Previous pathological (Trapp et al 
1999) and MRI studies (De Stefano et al 1999) have shown 
that axonal damage secondary to inﬂ  ammation occurs early 
in the course of MS. Further, longitudinal observational 
(Weinshenker et al 1995) and MRI studies (O’Riordan 
et al 1998) have indicated that early pathological events 
are predictive of the future course of the disease. Imaging 
studies (Miller et al 1988; Paty et al 1988; Baum et al 1990) 
have contributed to the evidence that inﬂ  ammatory activity 
underlying clinical relapses reﬂ  ects a chronic process start-
ing before the ﬁ  rst episode of acute neurological impair-
ment. It continues between relapses, becoming increasingly 
entrenched and difﬁ  cult to control due to the early tissue 
injury that leads to the exposure of a progressively wider 
variety of autoantigens, in accordance to a phenomenon 
known as epitope spreading (Tuohy et al 1998).
The ETOMS trial (Early Treatment Of Multiple sclerosis 
Study group) (Comi et al 2001) studied a cohort of 309 
patients who had presented with a single neurological episode 
suggestive of MS, and whose MRI scan was compatible with 
spatial dissemitated demyelinization. The inclusion criteria 
identiﬁ  ed patients who were at high risk of developing 
clinically deﬁ  nite multiple sclerosis (CDMS) according to 
Poser’s diagnostic criteria (Poser et al 1983). Patients were 
randomized in two balanced groups receiving either INF β 
1a 22 µg q.w. or placebo. The study lasted 2 years, and 278 
(90%) patients completed the follow-up according to the 
study protocol. The primary outcome measure was the con-
version to CDMS, as deﬁ  ned by the occurrence of a second 
relapse. Secondary study outcomes included change in the 
Scripps Neurologic Rating Scale (SNRS) score (Koziol et al 
1999), and MRI measures such as the number of T2 active 
lesions – deﬁ  ned as new or enlarging T2 lesions, the number 
of enhancing T1 lesions, the number of patients without an 
active MRI scan, and the yearly changes of hyperintense T2 
lesion volume. INF β 1a 22 µg showed advantages over pla-
cebo on both primary and secondary outcomes. The percent-
age of patients converting to CDMS was signiﬁ  cantly lower 
in the INF β 1a 22 µg group compared to placebo (34% versus 
45%, p = 0.047). Other clinical endpoints, although not stated 
as primary or secondary outcomes, conﬁ  rmed the therapeutic 
effect of the medication. Time to conversion to CDMS was 
more than doubled in the INF β 1a 22 µg group (569 days for 
the treated group versus 252 days for the placebo group in 
the 30th centile; p = 0.034), and annual relapse rate was 0.33 
in the INF β 1a 22 µg group and 0.43 in the placebo group 
(p = 0.045). Neuroimaging results were available for a large 
subgroup of patients in each of the two arms, and supported 
the beneﬁ  t of active treatment versus placebo, as both T2 
active lesions and lesion volume were signiﬁ  cantly reduced 
by INF β 1a. Furthermore, a post-hoc imaging analysis of 
brain volume by the ETOMS study group (Filippi et al 2004) 
demonstrated that early treatment reduced the progressive 
loss of brain tissue, a marker of axonal injury and matrix 
destruction associated with irreversible disability.
The results of the trial were in agreement with those of 
the Controlled High-risk subjects Avonex Multiple sclerosis 
Prevention Study (CHAMPS) (Jacobs et al 2000), which 
assessed the potential of INF β 1a 30 µg i.m. q.w. in reducing 
the risk of developing CDMS in patients with CIS. Compared 
to the CHAMPS trial, the results from the ETOMS study 
were more remarkable for several reasons. The patient cohort 
at baseline was representative of a more severe and active 
disease, as it included patients with multifocal onset and a Neuropsychiatric Disease and Treatment 2008:4(2) 330
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higher MRI lesion numbers, the study follow-up was longer, 
the patient retention higher, and the beneﬁ  cial effect of treat-
ment associated with a frequency of treatment administration 
that had proved of limited efﬁ  cacy in RRMS, suggesting 
that the approved standard frequency of administration for 
RRMS might have achieved even better outcome. Consistent 
results came from similar studies with the INF β 1-b 8 MIU 
s.c q.o.d. preparation which not only showed how early treat-
ment in patients with CIS delayed conversion to clinically 
deﬁ  nite MS (Kappos et al 2006) but recently underscored 
its potential to prevent the development of ﬁ  xed disability 
(Kappos et al 2007).
The suitability of the drug therapy after a ﬁ  rst disease epi-
sode has gained more relevance following the introduction of 
the McDonald’s diagnostic criteria (McDonald et al 2001) and 
its recent revision (Polman et al 2005). These criteria, accept-
ing the Barkhof/Tintore criteria for providing MRI evidence 
of dissemination in space, allow an early diagnosis of multiple 
sclerosis in patients with CIS, that otherwise would have to 
await a second clinical episode for MS diagnosis. Accord-
ing to longitudinal MRI and clinical studies of CIS cohorts 
(O’Riordan et al 1998) it is now possible to estimate the risk 
of conversion to CDMS. Fullﬁ  llment of MRI criteria of dis-
semination in space and in time after a ﬁ  rst episode suggestive 
of MS could lead to a screening of patients in terms of risk of 
conversion (Kortweg et al 2006) and to an adequate and rea-
sonable efﬁ  cacy-risk weighted early initiation of treatment.
SPECTRIMS trial
Evidence of efﬁ  cacy of INFs β in SPMS has been more 
controversial. An European randomized, placebo-controlled, 
double-blind trial (European Study Group on Interferon beta-
1b in Secondary Progressive MS 1998) demonstrated that INF 
β 1b reduced the conﬁ  rmed 1-point EDSS progression rate 
(–22%; p = 0.0008), the study primary endpoint, as well as the 
clinical attack rate (–31%; p = 0.0002), the MRI attack rate 
(–78%; p = 0.0008), the white matter lesion burden (–13%; 
p = 0.0001), and more relevant the likelihood of becoming 
wheelchair bound during the study (–33%; p = 0.01). At 
variance with these results, a North American trial (Goodkin 
et al 2000) failed to replicate the favorable impact of INF 
β 1b on the 1-point conﬁ  rmed EDSS progression rate (trial 
primary endpoint), although positive ﬁ  ndings were reported 
in secondary outcomes clinical attack rate, MRI attack rate 
and white matter lesion burden. Discrepancy between results 
of the two trials was attributed to the fewer attack rate in the 
North American cohort, and was taken as a proof of efﬁ  cacy 
of INF β 1b on SPMS with superimposed relapses.
On the basis of these previous trials, the SPECTRIMS 
study group (SPECTRIMS Study Group 2001) conducted a 
multicenter, randomized, parallel-group, placebo-controlled 
study, assessing INF β 1a 22 and 44 µg s.c. t.i.w. in SPMS 
patients. The trial failed to show a beneﬁ  t on the primary 
endpoint time to confirmed progression, defined as an 
increase from baseline by at least 1 point or 0.5 if baseline 
EDSS was  5.5 (the hazard ratio 0.8 for 44 µg s.c. t.i.w. 
did not signiﬁ  cantly differ from that in the placebo group; 
p = 0.146). However, a favorable effect was reported on 
clinical attack rate (0.50 per year with the active treatment 
versus 0.71 per year with placebo; p   0.001 for both doses), 
on other secondary exacerbation-related outcomes, and on 
a composite score resulting from the combination of ﬁ  ve 
major clinical and MRI measures. MRI ﬁ  ndings (Li et al 
2001) were detailedly reported apart, and demonstrated a 
favorable effect of the treatment (reduced median numbers 
of active lesions per patient per scan and white matter lesion 
burden). When the results were reconsidered in a post-hoc 
analysis by separating patients into those with and without 
superimposed relapses, a signiﬁ  cant beneﬁ  t on the conﬁ  rmed 
EDSS progression rate was detected in patients who con-
tinued to experience relapse, and positive MRI results were 
also of greater magnitude. However caution should be used 
to interpret these positive ﬁ  ndings as this analysis was not 
planned when the study was designed and both treatment 
doses were combined in the calculation.
Surprisingly, the study showed also a signiﬁ  cant beneﬁ  t 
on disability progression in women, and treatment-by-sex 
interactions were also reported for MRI measures. The 
authors could not provide a deﬁ  nite explanation for this ﬁ  nd-
ing, as neither the effect of chance nor a better responsiveness 
of women to INF could be excluded.
On the basis of these results, the treatment was not 
acknowledged as effective in SPMS notwithstanding the 
potential beneﬁ  t in patients with superimposed relapses which 
suggested that treatment in the early phase of the disease, 
when relapses are a dominant feature, may be paramount to 
achive a better therapeutic response. Discrepancy of these 
SPECTRIMS trial ﬁ  ndings with the European INF β 1b trial 
could be explained by the shorter follow-up of the latter, due 
to early termination, higher rate of treatment discontinuation, 
and higher proportion of patients with pre-study relapses. Per-
centage of patients with pre-study relapse was more compa-
rable to the North American Trial (European INF β 1b 70%, 
North American INF β 1b study 45%, SPECTRIMS 48%). 
The positive effect on relapses and MRI activity not accom-
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of a neurodegeneration dissociated from inﬂ  ammatory events 
or of the existence of a time lag between inﬂ  ammmation and 
degeneration, which again strongly supported the usefulness 
of an early treatment. Table 2 shows a summary of clinical 
trials that have assessed INF β 1a 22 or 44 µg s.c. t.i.w. in 
different clinical forms of MS.
The inﬂ  uence of NAbs on IFN β 1a 
efﬁ  cacy
The detrimental effect of NAbs was observed after 18 months 
of treatment, and thereby short term clinical trials could lead to 
misinterpret the real impact of their development on treatment 
response (Vartanian et al 2004). Indeed, in the PRISMS trial 
the development of NAbs did not affect the mean relapse count 
for the 22 µg nor for 44 µg groups, and did not inﬂ  uenced the 
overall results. However, at the 4 years follow-up the effect 
of NAbs became more relevant, as NAbs-positive patients 
experienced slightly more relapses than NAbs-negative in 
both dose groups. NAbs were less frequently associated to 
the 44 µg dose regimen, but their impact on relapse rate was 
greater, and exclusion of NAb-positive patients strengthened 
the dose effect on relapse. NAbs impact was appreciated also 
on MRI measures, as NAbs-positive patients had a higher 
number of T2 active lesions, the lesion burden being increased 
in NAbs-positive patients and decreased in NAbs-negative 
ones within the 44 µg group.
Whereas the appearance of NAbs is not an early phe-
nomenon, and its signiﬁ  cance can be appreciated over lon-
ger follow-up, it is noteworthy that longer follow-up also 
documented a higher proportion of patients who developed 
NAbs seroreverted to NAb-negative status. Kappos et al 
(2006) reported in their 7- to 8-year follow-up study of the 
PRISMS cohort that fewer patients in the LTFU cohort were 
NAbs-positive at their LTFU assessment than at earlier 
assessments. They observed also that at this time point an 
analysis of the impact of NAbs on the efﬁ  cacy of the drug was 
hindered by many factors: few patients from a large cohort 
were interested, differential withdrawal of patients by NAbs 
status, the post hoc nature of the NAb efﬁ  cacy analysis, NAbs 
development not always preceding EDSS progression, and 
variability in titer measures. In the EVIDENCE trial, NAbs 
developed more frequently in the IFN β 1a 44 µg s.c. t.i.w 
group than in the lower dose regimen. By using the anytime 
positive deﬁ  nition of NAbs-positivity, ie, considering only 
patients who remained NAbs positive untill the last assess-
ment, it could be appreciated that their clinical impact was 
minimal during the study and only some effects were evident 
on MRI outcomes. In the SPECTRIMS trial, patients were 
tested for NAbs at 6-month intervals. The study shared the 
same limits of the PRISMS trial, a short duration of follow-
up and a small number of patients involved, for a reliable 
analysis of the impact of NAbs development. However, the 
results conﬁ  rmed that the rate of NAbs development was 
higher for the 22 µg group, the seroconversion occurred 
generally after the ﬁ  rst 18 months, and the positive status 
tended to affect drug efﬁ  cacy on relapse rate in the 44 µg 
group, without any impact on the primary outcome.
Review of the selected phase IV studies do not provide 
additional information. According to a recent consensus 
(Hartung et al 2005) the immunogenicity of IFN β 1a 22 
and 44 µg s.c. t.i.w. seems to be intermediate between that 
of IFN β 1b 8 MIU s.c. q.o.d., the most immunogenic drug, 
and IFN β 1a 30 µg i.m. q.w., the least immunogenic drug. 
Reasons behind immunogenicity differences are manifold 
and not yet completely understood. It is likely that difference 
of dose, frequency and route of administration, structural drug 
characteristics, level of homology to the natural human IFN, 
differences in manufacturing, puriﬁ  cation, and formulation 
processes, all contribute to the variable immunogenicity of 
compounds.
Little information exists regarding how long NAbs last 
over continued treatment, as in some cases NAbs disappear 
over time (Rice et al 1999). It is likely that during the period 
of NAbs positive status, clinical beneﬁ  ts of the drug are 
abolished or diminished. Evidence that NAbs may affect 
drug efﬁ  cacy encouraged the research of different IFN β 1a 
22 or 44 µg formulations, hopefully less immunogenic and 
alternative to the current preparation. An ongoing phase III 
trial is assessing the antigenicity of a new fetal bovine serum 
(FBS)-free/human serum albumin (HSA)-free formulation of 
IFN β 1a. The producer has already submitted a supplemental 
Biologics Licence Application (sBLA) to the US Food and 
Drug Administration (FDA) and a variation to the current 
Marketing Authorization to the European Medicines Agency 
(EMEA) for the new IFN β 1a formulation. An interim analy-
sis of data from a Phase III clinical trial in patients with RR 
MS presented at the last ECTRIMS meeting (Giovannoni 
et al 2006) showed a substantial improvement in overall toler-
ability of the new formulation, as measured by injection site 
reactions, and a remarkable lower incidence of NAbs.
Safety and tolerability
Data on safety and tolerability of IFN β 1a 22 or 44 µg s.c. 
t.i.w. in MS patients were derived by PRISMS study and its 
cross-over extensions, EVIDENCE, ETOMS, and SPEC-
TRIMS trials, and selected post-marketing studies.Neuropsychiatric Disease and Treatment 2008:4(2) 332
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Table 2 Summary of trials with IFN β 1 a 22 µg and 44 µg in the different indications
CIS ETOMS
Primary outcome Proprortion of patient developing CDMS reduced in IFN β 1a group compared to placebo group (34% vs 45%); 
p = 0.047
Secondary clinical outcomes Time at which 30% of patients had converted to CDMS longer for IFN β 1a group compared to placebo group (569 
vs 252 days) p = 0.034
Annual relapse rate reduced in IFN β 1a group compared to placebo group (0.33 vs 0.43) p = 0.045
Secondary MRI outcomes Median number of active T2 lesion per patient per scan reduced in IFN β 1a group compared to placebo group
(2.0 vs 3.0) p   0.001
Median absolute change in T2 lesion volume (mm3) reduced in IFN β 1a group compared to placebo group (–487 vs 
–299) p = 0.002
RRMS PRISMS
Primary outcome Relapse rate at year 2 lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (1.82, 1.73 vs 2.56) p   0.005
Secondary clinical outcomes Percentage relapse free patients over 1 year higher in IFN β 1a 22 µg and 44 µg groups compared to placebo (37%, 
45% vs 22%) p   0.005
Percentage relapse free patients over 2 years higher in IFN β 1a 22 µg and 44 µg groups compared to placebo (27%, 
32% vs 16% placebo) p   0.05 and p   0.005
Mean moderate or severe relapses in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.71, 0.62 vs 0.99) 
p   0.005
Mean steroid courses lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.97, 0.75 vs 1.39) p   0.05 
and p   0.005
Mean hospital admissions lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.38, 0.25 vs 0.48) 
p   0.005 only for IFN β 1a 44 µg group compared to placebo
Mean changes in EDSS lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.23, 0.24 vs 0.48) p   0.05
Secondary MRI outcomes Median lesion volume percentage change over baseline lower in IFN β 1a 22 µg and 44 µg groups compared to 
placebo (−1.2%, −3.8% vs +10.9%) p   0.0001
Median number of active lesions lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (−67%, −78%) 
p   0.0001
SPMS SPECTRIMS
Primary outcome Time to conﬁ  rmed progression in disability not signiﬁ  cantly affected by treatment with IFN β 1a 44 µg compared to 
placebo (HR 0.83; 95 CI 0.65-1.07) p = 0.146
Secondary clinical outcomes Mean relapse rate lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.50, 0.50 vs 0.71) p   0.001
Median time to ﬁ  rst exacerbation longer in the IFN β 1a 44 µg group compared to placebo (494 vs 281 days, HR 
0.77) p = 0.034
Median time between ﬁ  rst and second exacerbation lower in IFN β 1a 22 µg and 44 µg groups compared to placebo 
(572, 511 vs 279 days) p   0.001
Mean moderate and severe exacerbations per person-year lower in IFN β 1a 22 µg and 44 µg groups compared to 
placebo (0.26, 0.27 vs 0.39) p = 0.002, p = 0.003
Mean steroid courses lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.31, 0.34 vs 0.52) p = 0.001 
and p = 0.006
Mean hospital admission lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.14, 0.15 vs 0.22) 
p = 0.006 and p = 0.005
Secondary MRI outcomes Lesion burden change over three years in IFN β 1a 22 µg and 44 µg groups compared to placebo (−32,−4 vs +263) 
p   0.001
T2 active lesions/patient/scan lower in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.17, 0.20 vs 0.60) 
p   0.001
Median CU active lesions/patient/ in IFN β 1a 22 µg and 44 µg groups compared to placebo (0.11, 0.22 vs 1.0) 
p   0.001 and p   0.01
Abbreviations: CIS, clinically isolated syndrome; CI, conﬁ  dence interval 95%; CDMS, clinically deﬁ  nite multiple sclerosis; CU, combined unique; ETOMS, Early Treatment Of 
Multiple sclerosis Study group; HR, hazard ratio; PRISMS, Prevention of Relapses and disability by Interferon β-1a Subcutaneously in Multiple Sclerosis; RRMS, Relapsing Remitting 
Multiple Sclerosis; SPMS, Secondary Progressive Multiple Sclerosis; SPECTRIMS, Secondary Progressive Efﬁ  cacy Clinical Trial of Recombinant Interferon-beta-1a in MS.Neuropsychiatric Disease and Treatment 2008:4(2) 333
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In the PRISMS trial and its extensions, treatment with 
both doses of IFN β 1a s.c. t.i.w. was generally well toler-
ated. Adverse events were common but mild and manage-
able. These events included headache, ﬂ  u-like symptoms, 
injection-site reactions, fatigue, myalgia, and fever. Labora-
tory abnormalities without clinical manifestations were also 
reported, as lymphopenia, increased alanine aminotrans-
ferase, leucopenia, increased aspartate aminotransferase, 
granulocytopenia. Similar adverse reactions were observed 
in the placebo arm, except injections-site reactions and labo-
ratory abnormalities signiﬁ  cantly more frequent in active 
treated patients. No difference was reported between the 
two dose regimens with regard to injection-site reactions, 
but laboratory abnormalities were more frequently associ-
ated with the higher dose. Hematologic abnormalities and 
elevation of liver enzymes were reduced during the second 
year of treatment.
The 4-year follow-up safety assessment conﬁ  rmed that 
treatment was generally well tolerated, and ﬂ  u-like symp-
toms, injection-site reactions, and laboratory abnormalities 
occurred to a lower extent over time. As expected, adverse 
events were more frequent in the cross-over group com-
pared to early placebo treatment. Drug discontinuation due 
to adverse events was slightly higher at the higher dose, 
but more patients at the lower dose withdrew for disease 
progression. The most common adverse events leading 
to patient discontinuation were depression and injection-
site reactions. Very rarely a skin necrosis was reported. 
Injection-site reactions decreased in frequency at 3 and 4 
years of treatment, and were more often associated with the 
higher dose regimen.
Depression was not signiﬁ  cantly associated with active 
drug, and over 3 and 4 years of treatment rate was compa-
rable with that observed among patients receiving placebo 
at the initial phase of the study. Depressive symptoms were 
strongly associated with depression at baseline (Patten and 
Metz 2001). Association between treatment and depression 
was ruled out also in a study conducted on the SPMS cohort 
of the SPECTRIMS trial (Patten and Metz 2002). Depression 
ratings were obtained from 365 subjects treated either with 
IFN β 1a or with placebo: no signiﬁ  cant differences between 
groups emerged over 36-month follow-up.
Data of a 7- to 8-year follow-up study conﬁ  rmed a 
generally manageable drug tolerability proﬁ  le and no new 
safety concerns were identiﬁ  ed. Injection-site reactions 
were the most frequently reported adverse events, while 
others events including laboratory abnormalities occurred 
less frequently.
The EVIDENCE trial showed that IFN β 1a 22 and 44 
µg s.c. t.i.w. were more frequently associated with injection-
site reactions and asymptomatic hepatic and white blood cell 
abnormalities, compared to IFN β 1a 30 µg i.m. q.w. These 
events tended to reduce over time, and patients with NAbs 
had fewer IFN-related adverse events. Analysis of ETOMS 
and SPECTRIMS trials did not added any additional infor-
mation on safety and tolerability of the drug.
Thyroid, hepatic, and hematological 
abnormalities
Pre-existing and incident thyroid disease in multiple sclero-
sis patients receiving IFN β 1b has been reported (Monzani 
et al 2004). Similarly, clinically signiﬁ  cant abnormal thyroid 
laboratory values were described during the PRISMS study 
but none caused drug discontinuation or dose reduction. A 
recent study conﬁ  rmed that both incidental thyroid autoim-
munity and dysfunction occured in a large sample of RR MS 
patients treated with both IFN β 1a and 1b, namely within 
the ﬁ  rst year of treatment. However, thyroid dysfunction was 
generally subclinical and transient, and never associated with 
treatment discontinuation (Caraccio et al 2005).
Two reviews have addressed hepatic dysfunction and 
hematologic events associated with IFN β 1a, combining 
data from randomized clinical trials and post-marketing 
surveillance (Francis et al 2003; Rieckmann et al 2004). 
Raised hepatic aminotransferase levels were mostly asymp-
tomatic, occurred more commonly in the ﬁ  rst 12 months of 
treatment, were frequency-dose related, and resolved mostly 
spontaneously or with dose adjustment. Post-marketing 
studies conﬁ  rmed these ﬁ  ndings, but generally reported 
a greater elevation of liver enzymes (Tremlett and Oger, 
2004a; Tremlett and Oger, 2004b; Tremlett et al 2004c). 
Post-marketing surveillance of IFN β 1a included 130,000 
patient-years, and reported 30 cases of serious symptomatic 
hepatic dysfunction, 2 cases requiring liver transplantation.
A review of pooled data on hematological events 
(Rieckmann et al 2004) showed only mild, asymptomatic, 
reversible, dose-related abnormalities, with little impact on 
adherence to treatment. They tend to occur during the ﬁ  rst 
6 months of treatment and consisted of decreases in white 
blood cells, neutrophils, lymphocytes, and platelet counts. 
Post-marketing surveillance data of IFN β 1a showed that 
hematological accounted for 8.6% of all reported adverse 
events, and only 12.8 of them were severe (Murdoch and 
Lyseng-Williamson 2004).
In our selected ancillary studies, IFN β 1a was well toler-
ated and adverse events were comparable with those reported Neuropsychiatric Disease and Treatment 2008:4(2) 334
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in pivotal trials. Injection-site reactions were more frequent 
with for IFN β 1a s.c. preparations. Rio et al (2005) reported 
3 cases of urticaria and angioedema that were not observed 
in pivotal trials: reactions subsided with drug discontinuation 
and appropriate treatment. Limmoth et al (2007) considered 
number of patients who switched therapy as a partial indirect 
measure of tolerability, and showed fewer switches due to 
injection-site reaction in IFN β 1a i.m group compared to s.c. 
preparations. However, the authors acknowledged that drug 
discontinuation and switch to alternative therapy was often 
related to poor efﬁ  cacy, and that IFN β 1a 44 µg s.c. t.i.w. was 
often used as second treatment in these cases. Milanese et al 
(2005) claimed that shift to lower dose and lower frequency 
occurred more often when discontinuation of previous treat-
ment was due to toxicity and lack of compliance, whereas 
shift to higher doses and frequencies was driven mainly by 
clinician decision toward a perceived poor response.
Conclusions
Pivotal trials and post-marketing studies have estabilished 
the efﬁ  cacy of INF β 1a 22 and 44 µg s.c. t.i.w. on reduc-
tion of disease activity measured by clinical outcomes and 
MRI surrogate measures. Theoretically less immunogenicity 
compared to INF β 1b, and treatment at higher doses and 
higher frequency favor INF β 1a 22 and 44 µg s.c. t.i.w. 
compared to other INF β formulations, but further head-
to-head comparison studies are warranted to conﬁ  rm this 
potential. Additional studies show that early drug treatment 
is beneﬁ  cial in patients with early clinical manifestations 
and extends time to conversion to CDMS. Current evidences 
of beneﬁ  t in patients with SPMS are not strong enough to 
support its use in this clinical MS subtype. Results of clinical 
trials and post-marketing surveillance of INF β 1a 22 and 
44 µg s.c. consistently show that the treatment is generally 
well tolerated, even on long-term basis. Adverse reactions 
generally occur at treatment initiation and are mild and 
manageable.
Disclosures
The authors have no conﬂ  icts of interest to disclose.
References
Antonetti F, Finocchiaro O, Mascia M, et al. 2002. A comparison of the 
biologic activity of two recombinant IFN-beta preparations used in 
the treatment of relapsing-remitting multiple sclerosis. J Interferon 
Cytokine Res, 22:1181–4.
Baum K, Nehrig C, Schörner W, et al. 1990. Long-term follow-up of MS:
disease activity detected clinically and by MRI. Acta Neurol Scand, 
82:191–6.
Benson K, Hartz AJ. 2000. A comparison of observational studies and 
randomized, controlled trials N Engl J Med, 342:1878–86.
Bertolotto A, Gilli F, Sala A, et al. 2001. Evaluation of bioavailability of 
three types of IFN-β in multiple sclerosis patients by a new quantitative-
competitive-PCR method for MxA quantiﬁ  cation. J Immunol Methods, 
256:141–52.
Bertolotto A, Deisenhammer F, Gallo P, et al. 2004. Immunogenicity
of interferon beta:differences among products. J Neurol, 
251(Suppl 2):15–24.
Biernacki K, Antel JP, Blain M, et al. 2005. Interferon beta promotes nerve 
growth factor secretion early in the corse of multiple sclerosis. Arch 
Neurol, 62:119–24.
Bonavita S, Dinacci D, Lavorgna L, et al. 2006. Treatment of multiple 
sclerosis with interferon beta in clinical practice:2-year follow-up data 
from the South Italy Mobile MRI Project. Neurol Sci, 27:365–8.
Caraccio N, Dardano A, Manfredonia F, et al. 2005. Long-term follow-up 
of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b 
therapy:predictive factors of thyroid disease development and duration. 
J Clin Endocrinol Metab, 90:4133–47.
Cohen RA, Kessler HR, Fisher M. 1993. The expanded disability status 
scale (EDSS) as a predictor of impairments of functional activities of 
daily living in multiple sclerosis. J Neurol Sci, 115:132–5.
Comi G, Filippi M, Barkof F, et al. 2001. Effect of early treatment on conversion 
to deﬁ  nite multiple sclerosis:a randomized study. Lancet, 357:1576–82.
Compston A, Coles A. 2002. Multiple sclerosis. Lancet, 359:1221–31.
Concato J, Shah N, Horwitz RI. 2000. Randomized, controlled trials, 
observational studies, and the hierarchy of research design. N Engl J 
Med, 342:1887–92.
Confavreux C, Vukusic S, Moreau T, et al. 2000. Relapses and progression 
of disability in multiple sclerosis. N Engl J Med, 343:1430–8.
de Andres C, Aristimuno C, de Las Heras V, et al. 2007. Interferon beta-1a 
therapy enhances CD4+ regulatory T-cell function:an ex vivo and 
in vitro longitudinal study in relapsing-remitting multiple sclerosis. 
J Neuroimmunol, 182:204–11.
De Stefano N, Narayanan S, Pelleties D, et al. 1999. Evidence of early 
axonal damage in patients with multiple sclerosis [abstract]. Neurol-
ogy, 52(Suppl 2):378.
Dhib-Jalbut S. 2002. Mechanisms of action of interferons and glatiramer 
acetate in multiple sclerosis. Neurology, 23(8 Suppl 4):S3–9.
Durelli L, Verdun E, Barbero P, et al. 2002. Every-other-day interferon 
beta-1b versus once-weekly interferon beta-1a for multiple sclerosis:
results of a 2-year prospective randomised multicentre study (INCO-
MIN). Lancet, 359:1453–60.
Filippi M, Rovaris M, Inglese M, et al. 2004. Interferon beta-1a for brain 
tissue loss in patients at presentation with syndromes suggestive of 
multiple sclerosis:a randomized, double-blind, placebo-controlled trial. 
Lancet, 364:1489–96.
Francis GS, Grumser Y, Altieri E, et al. 2003. Hepatic reactions during 
treatment with interferon-β-1a:incidence and clinical signiﬁ  cance. 
Drug Saf, 26:815–27.
Etemadifar M, Janghorbani M, Shaygannejad V. 2006. Comparison of 
Betaferon, Avonex, and Rebif in treatment of relapsing-remitting 
multiple sclerosis. Acta Neurol Scand, 113:283–7.
European Study Group on Interferon beta-1b in Secondary Progressive MS. 
1998. Placebo-controlled multicentre randomized trial of interferon 
beta-1b in treatment of secondary progressive multiple sclerosis. 
Lancet, 352:1491–7.
Galboiz Y, Shapiro S, Lahat N, et al. 2001. Matrix metalloproteinases and 
their tissue inhibitors as markers of disease subtype and response to 
interferon-β therapy in relapsing and secondary-progressive multiple 
sclerosis patients. Ann Neurol, 50:443–51.
Ghezzi A, Amato MP, Capobianco M, et al. 2005. Immunomodulatory 
Treatment of Early onset MS Group. Disease-modifying drugs in 
childhood-juvenile multiple sclerosis:results of an Italian co-operative 
study. Mult Scler, 11:420–4.
Ghezzi A, Amato MP, Capobianco M, et al. 2007. Immunomodulatory 
Treatment of Early-onset MS (ITEMS) Group. Treatment of early-
onset multiple sclerosis with intramuscular interferonbeta-1a:long-term 
results. Neurol Sci, 28:127–32.Neuropsychiatric Disease and Treatment 2008:4(2) 335
Efﬁ  cacy of Rebif® in multiple sclerosis
Giorelli M, De Blasi A, Defazio G, et al. 2002. Differential regulation of 
membrane bound and solubile ICAM 1 in human endothelium and 
blood mononuclear cells:effects of interferon beta-1a. Cell Commun 
Adhes, 9:259–72.
Giovannoni G, Barbarash OL, Jaber A, et al. 2006. Reduced immunogenicity 
with a new formulation of interferon-beta-1a (Rebif):24 week results of 
a phase IIIb trial study [abstract]. Mult Scler, 12(Suppl 1):192.
Goodkin DE, North American Study Group. 2000. Interferon beta-1b in 
secondary progressive MS:clinical and MRI results of a 3-year random-
ized controlled trial [abstract]. Neurology, 54:2352.
Haas J, Firzlaff M. 2005. Twenty-four-month comparison of immuno-
modulatory treatments – a retrospective open label study in 308 RRMS 
patients treated with beta interferons or glatiramer acetate (Copaxone). 
Eur J Neurol, 12:425–31.
Hartung HP, Munschauer III F, Schellekens H. 2005. Signiﬁ  cance of neutral-
izing antibodies to interferon beta during treatment of multiple sclerosis:
expert opinions based on Proceedings of an International Consensus 
Conference. Eur J Neurol, 12:588–601.
Harzheim M, Stepien-Mering M, Schroder R, et al. 2004. The expression 
of microﬁ  lament-associated cell-cell contacts in brain endothelial 
cells is modiﬁ  ed by IFN-beta1a (Rebif). J Interferon Cytokine Res, 
24:711–16.
Jacobs LD, Cookfair DL, Rudick RA, et al. 1996. Intramuscular interferon 
beta-1a for disease progression in exacerbating-remitting multiple 
sclerosis. Ann Neurol, 39:285–94.
Jacobs LD, Beck RW, Simon JH, et al. 2000. Intramuscular interferon 
beta-1a therapy initiated during a ﬁ  rst demyelinating event in multiple 
sclerosis. N Eng J Med, 343:898–904.
Juni P, Altman DG, Egger M. 2001. Systematic reviews in health care:
assessing the quality of controlled trials. Br Med J, 323:42–6.
Kappos L, Moeri D, Radue EW, et al. 1999. Predictive value of gadolinium-
enhanced magnetic resonance imaging for relapse rate and changes in 
disability or impairment in multiple sclerosis:a meta-analysis. Gado-
linium MRI Meta-analysis Group. Lancet, 353:964–9.
Kappos L, Polman CH, Freedman MS, et al. 2006. Treatment with inter-
feron beta-1b delays conversion to clinically deﬁ  nite and McDonald 
MS in patients with clinically isolated syndromes. Neurology, 
67:1242–9.
Kappos L, Traboulsee A, Costantinescu C, et al. 2006. Long-term subcu-
taneous interferon beta-1a therapy in patients with relapsing-remitting 
MS. Neurology, 67:944–53.
Kappos L, Freedman MS, Polman CH et al. BENEFIT Study Group. 2007. 
Effect of early versus delayed interferon beta-1b treatment on disabil-
ity after a ﬁ  rst clinical event suggestive of multiple sclerosis:a 3-year 
follow-up analysis of the BENEFIT study. Lancet, 370:389–97.
Koch-Henriksen N, Sorensen PS, Christensen T, et al. 2006. A randomized 
study of two interferon-beta treatments in relapsing-remitting multiple 
sclerosis. Neurology, 66:1056–60.
Korteweg T, Tintore M, Uitdehaag B, et al. 2006. MRI criteria for dis-
semination in space in patients with clinically isolated syndromes:a 
multicentre follow-up study. Lancet Neurol, 5:221–7.
Koziol JA, Lucero A, Sipe JC, et al. 1999. Responsiveness of the Scripps 
neurologic rating scale during a multiple sclerosis clinical trial. Can J 
Neurol Sci, 26:283–9.
Kurtzke JF. 1983. Rating neurologic impairment in multiple sclerosis:an 
expanded disability status scale (EDSS). Neurology, 33:1444–52.
Li DKB, Paty DW. 1999. Magnetic resonance imaging results of the 
PRISMS trial:a randomized, double-blind, placebo-controlled study of 
interferon-b1a in relapsing-remitting multiple sclerosis. Ann Neurol, 
46:197–206.
Li DKB, Zhao GJ, Paty DW et al. 2001. Randomized controlled trial of 
interferon-beta-1a in secondary progressive MS:MRI results [abstract]. 
Neurology, 56(Suppl 3):148–9.
Limmroth V, Malessa R, Zettl Uk J, et al. 2007. Quality Assessment in 
Multiple Sclerosis Therapy (QUASIMS).A comparison of interferon 
beta therapies for relapsing-remitting multiple sclerosis. J Neurol, 
254:67–77.
Liu C, Blumhardt LD. 1999. Randomized, double-blind, placebo-controlled 
study of interferon beta-1a in relapsing-remitting multiple sclerosis 
analyzed by area under disability/time curves. J Neurol Neurosurg 
Psychiatry, 67:451–6.
Liu C, Blumhardt LD. 2002. Randomized, double-blind, placebo-controlled 
study of subcutaneous interferon beta 1a in relapsing-remitting multiple 
sclerosis:a categorical disability trend analysis. Mult Scler, 8:10–14.
Lublin FD, Baier M, Cutter G. 2003. Effect of relapses on development of 
residual deﬁ  cit in multiple sclerosis. Neurology, 61:1528–32.
Malucchi S, Sala A, Gilli F, et al. 2004. Neutralizing antibodies reduce the 
efﬁ  cacy of betaIFN during treatment of multiple sclerosis. Neurology, 
62:2031–7.
McDonald WI, Compston A, Edan G, et al. 2001. Recommended diagnostic 
criteria for multiple sclerosis:guidelines from the International Panel on 
the diagnosis of multiple sclerosis. Ann Neurol, 50:121–7.
Milanese C, La Mantia L, Palumbo R, et al. 2003. A post-marketing study 
on interferon b 1b and 1a treatment in relapsing-remitting multiple 
sclerosis:different response in drop-outs and treated patients. J Neurol 
Neurosurg Psychiatry, 74:1689–92.
Miller DH, Rudge P, Johnson G, et al. 1988. Serial gadolinium enhanced 
magnetic resonance imaging in multiple sclerosis. Brain, 111:927–39.
Monzani F, Caraccio N, Dardano A, et al. 2004 Thyroid autoimmunity and 
dysfunction associated with type I interferon therapy. Review. Clin 
Exp Med, 3:199–210.
Murdoch D, Lyseng-Williamson KA. 2005. Subcutaneous recombinant 
interferon-beta-1a (Rebif): a review of its use in relapsing-remitting 
multiple sclerosis. Drugs, 65:1295–312.
Noseworthy JH, Vandervort MK, Wong CJ, et al. 1990. Interrater variability 
with the expanded disability status scale (EDSS) and functional systems 
(FS) in a multiple sclerosis clinical trial. Neurology, 40:971–5.
O’Riordan JI, Thompson AJ, Kingsley DP, et al. 1998. The prognostic value 
of brain MRI in clinically isolated syndromes of the CNS. A 10-year 
follow-up. Brain, 121:495–503.
Paolillo A, Pozzilli C, Giugni E, et al. 2002. A 6-year clinical and MRI 
follow-up study of patients with relapsing-remitting multiple sclerosis 
treated with Interferon-beta. Eur J Neurol, 9:645–55.
Panitch H, Goodin DS, Francis G, et al. for the EVIDENCE Study Group 
and the University of British Columbia MS/MRI Research Group. 
2002. Randomized, comparative study of interferon beta-1a treatment 
regimens in MS. The EVIDENCE trial. Neurology, 59:1496–506.
Patten SB, Metz LM. 2001. Interferon β-1a and depression in relapsing-
remitting multiple sclerosis:an analysis of depression data from the 
PRISMS clinical trial. Mult Scler, 7:243–8.
Patten SB, Metz LM. 2002. Interferon β1a and depression in secondary pro-
gressive MS:Data from the SPECTRIMS Trial. Neurology, 59; 744–6.
Paty DW. 1988. Magnetic resonance imaging in the assessment of disease 
activity in multiple sclerosis. Can J Neurol Sci, 15:266–72.
Pohl D, Rostasy K, Gärtner J, Hanefeld F. 2005. Treatment of early onset 
multiple sclerosis with subcutaneous interferon beta-1a. Neurology, 
65:888–90.
Polman CH, Reingold SC, Edan G, et al. 2005. Diagnostic criteria for 
multiple sclerosis:2005 revisions to the “McDonald Criteria”. Ann 
Neurol, 58:840–6.
Poser CM, Paty DW, Scheinberg L, et al. 1983. New diagnostic criteria 
for multiple sclerosis:guidelines for research protocols. Ann Neurol, 
13:227–31.
PRISMS study group. 1998. Randomised double-blind placebo-controlled 
study of interferon beta-1a in relapsing/remitting multiple sclerosis. 
PRISMS (Prevention of Relapses and Disability by interferon β-1a 
in Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 
352:1498–504.
PRISMS Study Group, University of British Columbia MS/MRI Analysis 
Group. 2001. PRISMS-4:long term tolerability of interferon beta-1a in 
relapsing MS. Neurology, 56:1628–36.
Rice GPA, Paszner B, Oger J, et al. 1999. The evolution of neutralizing 
antibodies in multiple sclerosis patients treated with interferon β-1b. 
Neurology, 52:1277–9.Neuropsychiatric Disease and Treatment 2008:4(2) 336
Manfredonia et al
Rieckmann P, O’Connor P, Francis GS, et al. 2004. Haematological effects 
of interferon-β-1a (Rebif) therapy in multiple sclerosis. Drug Saf, 
27:745–56.
Rìo J, Tintore M, Nos C, Téllez N, et al. 2005. Interferon beta in 
relapsing-remitting multiple sclerosis – an eight years experience in a 
specialist multiple sclerosis center. J Neurol, 252:795–800.
Rothuizen LE, Buclin T, Spertini F, et al. 1999. Inﬂ  uence of interferon β-
1a dose frequency on PBMC cytokine secretion and biological effect 
markers. J Neuroimmunol, 99:131–41.
Rovaris M, Confavreux C, Furlan R, et al. 2006. Secondary progressive 
multiple sclerosis:current knowledge and future challenges. Lancet 
Neurol, 5:343–54.
Rudick RA, Antel J, Confavreux C, et al. 1996. Clinical outcomes assess-
ment in multiple sclerosis. Ann Neurol, 40:469–79.
Rudick RA, Lee JC, Simon J, et al. 2006. Signiﬁ  cance of T2 lesions in mul-
tiple sclerosis:a 13-year longitudinal study. Ann Neurol, 60:236–42.
Runkel L, Meier W, Pepinsky, et al. 1998. Structural and functional dif-
ferences between glycosylated and non-glycosylated forms of human 
interferon-beta (IFN-beta). Pharm Res, 15:641–649.
Simon JH, Jacobs LD, Campion M et al. and the Multiple Sclerosis Collab-
orative Research Group (MSCRG). 1998. Magnetic resonance studies 
of intramuscular interferon b-1a for relapsing multiple sclerosis. Ann 
Neurol, 43:79–87.
SPECTRIMS Study Group (Secondary Progressive Efficacy Clinical 
Trial of Recombinant Interferon-beta-1a in MS). 2001. Randomized 
controlled trial of interferon-beta-1a in secondary progressive MS. 
Neurology, 56:1505–13.
Sättler MB, Demer I, Williams SK, et al. 2006. Effects of interferon-beta-1a 
on neuronal survival under autoimmune inﬂ  ammatory conditions. Exp 
Neurol, 201:172–81.
Stürzebecher S, Maibauer R, Heuner A et al. 1999. Pharmacodynamic com-
parison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. 
J Interferon Cytokine Res, 19:1257–64.
Tenembaum SN, Segura MJ. 2006. Interferon beta-1a treatment in childhood 
and juvenile-onset multiple sclerosis. Neurology, 67:511–13.
The IFNβ Multiple Sclerosis Study Group. 1993. Interferon beta-1b is 
effective in relapsing-remitting multiple sclerosis:I. Clinical results of 
a multicenter, randomized, double-blind, placebo-controlled trial. The 
IFNβ Multiple Sclerosis Study Group. Neurology, 43:655–61.
The Once Weekly Interferon for MS Study Group. 1999. Evidence of 
interferon beta-1a dose response in relapsing-remitting MS:the OWIMS 
Study. The Once Weekly Interferon for MS Study Group. Neurology, 
53:679–86.
Thompson AJ, Polman CH, Miller DH, et al. 1997. Primary progressive 
multiple sclerosis. Brain, 120:1085–96.
Trapp BD, Ranschoff RM, Fisher et al. 1999. Neurodegeneration in 
multiple sclerosis:relationship to neurological disability. Neurosci-
entist, 5:48–57.
Tremlett HL, Oger J. 2004. Elevated aminotransferases during treatment 
with interferon-beta for multiple sclerosis:actions and outcomes. Mult 
Scler, 10:298–301.
Tremlett HL, Oger J. 2004. Hepatic injury, liver monitoring and the beta-
interferons for multiple sclerosis. J Neurol, 251:1297–303.
Tremlett HL, Yoshida EM, Oger J. 2004. Liver injury associated with 
the β-interferons for MS: a comparison between the three products. 
Neurology, 62:628–31.
Trojano M, Paolicelli D, Zimatore GB, et al. 2005. The IFNbeta treatment 
of multiple sclerosis (MS) in clinical practice. The experience at the 
MS center of Bari, Italy. Neurol Sci, 26(Suppl 4):179–82.
Tuohy VK, Yu M, Yin L. 1998. The epitope spreading cascade during pro-
gression of experimental autoimmune encephalomyelitis and multiple 
sclerosis. Immunol Rev, 164:93–100.
Vartanian T, Solberg Sorensen P, Rice G. 2004. Impact of neutralising anti-
bodies on the clinical efﬁ  cacy of interferon beta in multiple sclerosis. 
J Neurol, 251 (Suppl 2):25–30.
Wagstaff AJ, Goa KL. 1998. Recombinant interferon-β-1a:a review of its 
therapeutic efﬁ  cacy in relapsing-remitting multiple sclerosis. Biodrugs, 
10:471–94.
Weinshenker BG. 1995. The natural history of multiple sclerosis. Neurol 
Clin, 13:119–46.
Weinshenker BG, Bass B, Rice GPA, et al. 1989. The natural history of 
multiple sclerosis:a geographically based study: I. Clinical course and 
disability. Brain, 112:133–46.
Weinshenker BG, Rice GPA, Noseworthy JH, et al. 1991 The natural 
history of multiple sclerosis:a geographically based study. 4. Applica-
tions to planning and interpratation of clinical therapeutic trials. Brain, 
114:1057–67.
Williams GJ, Witt PL. 1998. Comparative study of the pharmacodynamic 
and pharmacologic effects of Betaseron and Avonex. J Interferon 
Cytokine Res, 18:967–75.
Wingerchuk DM, Weinshenker BG. 1999. The natural history of multiple 
sclerosis. Implications for trial design. Curr Opin Neurol, 12:345–9.
Yong VW, Chabot S, Stuve O, et al. 1998. Interferon beta in the treatment 
of multiple sclerosis:mechanisms of action. Neurology, 51:682–9.